BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BBT001 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BBT001\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06808477-1309@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:BBT001: Phase 1 readout est. (NCT06808477)
DESCRIPTION:BBT001\, phase 1\, Atopic Dermatitis.\nStudy: A Study of BBT001
  in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis 
 (AD)\nEstimated primary completion: 28 February 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bbt001#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06808477
URL:https://assetmemo.bio/drug/bbt001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07239947-1309@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:BBT001: Phase 1 readout est. (NCT07239947)
DESCRIPTION:BBT001\, phase 1\, Atopic Dermatitis.\nStudy: A Study of BBT001
  in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe
  Atopic Dermatitis (AD)\nEstimated primary completion: 31 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/bbt001#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07239947
URL:https://assetmemo.bio/drug/bbt001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07717905-1309@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:BBT001: Phase 1/2 readout est. (NCT07717905)
DESCRIPTION:BBT001\, phase 1/2.\nStudy: A Study to Evaluate the Safety\, To
 lerability\, Pharmacokinetics\, Immunogenicity\, Pharmacodynamics and Clin
 ical Activity of BBT001 Following Intravenous Administration in Participan
 ts With Chronic Spontaneous Urticaria (CSU)\nEstimated primary completion:
  31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bb
 t001#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07717905
URL:https://assetmemo.bio/drug/bbt001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
